- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02889575
Predictive Value of PIIINP and Urinary NGAL in Renal Function Recovery (PIIINP-NGAL)
Prospective Multicenter Study to Assess the Predictive Value of PIIINP and Urinary NGAL in Renal Function Recovery During Acute Tubular Necrosis
Acute Renal Failure (ARF) is defined by a severe, and usually reversible, glomerular filtration rate decreasing. Acute Tubular Necrosis (ATN) remain the major cause of ARF involving distress and destruction of tubular cells. This specific typology of ARF may evolve toward Chronic Renal Failure (CRF) concretizing a major public health issue.
Predict the progression of ARF towards CRF appears essential. The investigators believe that the PIIINP and urinary NGAL biomarkers may constitute robust biomarkers of progression risk towards CRF.
Studienübersicht
Status
Detaillierte Beschreibung
Acute Renal Failure (ARF) is defined by a severe, and usually reversible, glomerular filtration rate decreasing. Beside its frequency, ARF may be associated with severe prognostic. Thus, patient admitted in ICU and suffering of ARF requiring dialysis, had a higher risk of mortality up to 50%.
Tubulointerstitial nephropathies, particularly Acute Tubular Necrosis (ATN) remain the major cause of ARF, representing 45-50% of cases. The ATN is due to suffering and destruction of tubular cells which are very sensitive to ischemia-reperfusion lesions because tubular reabsorption functions require significant and constant energy intake. However, ATN represents a relatively homogeneous group in terms of acute kidney disease typology. Homogeneity and significant frequency compels ATN as an optimal model to study function recovery after ARF.
ARF constitutes a major public health issue. Actually, incidence of Chronic Renal Failure (CRF) after an ARF, due to ATN, is estimated between 19% and 31%. In addition 12.5% of patients with specific ARF presentation immediately reach End-stage Renal Disease (ESRD), and the occurrence of ARF requiring dialysis, triples the risk of chronic renal support.
Therefore, predict the progression of ARF towards CRF appears essential.
At this time, the investigators currently lack of reliable biomarkers to predict such progression. This pejorative kidney development is due to the persistence of intrarenal inflammation, rapid development of interstitial fibrosis and deficiency in tubular restoration. It involves complex mechanisms of inflammatory response, and vascular and tubular remodeling.
Two promising biomarkers of renal fibrosis, ARF occurrence and CRF progression risk appear in recent years: the Procollagen III N-terminal peptide (PIIINP) and the neutrophil gelatinase associated lipocalin (NGAL). The investigators believe that the PIIINP and urinary NGAL may constitute robust biomarkers of progression (or not) towards CRF in ARF context. Firstly, PIIINP is a good reflection of fibrosis process inside the kidney. Secondarily, NGAL is a marker of renal tubule remodeling after renal aggression. The combination of these two biomarkers could therefore efficiently reflect the balance tubular fibrosis/restoration and may allow optimal prediction of renal function recovery.
The investigators hypothesize that these two biomarkers may be used to assess the risk of CRF progression during ARF in ATN context.
Studientyp
Einschreibung (Tatsächlich)
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- off-age patient.
- ATN diagnosis based on 1) typical clinical environment (sepsis, nephrotoxicity...) 2) 50% decrease of glomerular filtration flow (according clearance MDRD) or more than 100micromol plasmatic creatinine increase. 3) no renal function improvement after efficient vascular filling (>750cc normal saline or equivalent).
- Consent.
Exclusion Criteria:
- ARF not related with ATN context.
- Life expectancy less than 3 months.
- Protocol refusal
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
PIIINP/Urinary Creatinine ratio levels between patients experimenting CRF or not.
Zeitfenster: 12months after initial diagnosis.
|
We expect to highlight different ratio PIIINP/Urinary Creatinine levels and evolution between patients experimenting CRF or not (defined less than 60 mL/min according MDRD formula).
|
12months after initial diagnosis.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
NGAL/Urinary Creatinine ratio levels between patients experimenting CRF or not.
Zeitfenster: 12, 18 and 24 months after initial diagnosis.
|
We expect to highlight different ratio NGAL/Urinary Creatinine levels and evolution between patients experimenting CRF or not (defined less than 60 mL/min according MDRD formula).
|
12, 18 and 24 months after initial diagnosis.
|
|
Correlation between NGAL/Urinary Creatinine and PIIINP/Urinary Creatinine ratios among patients with ARF.
Zeitfenster: 3, 6, 12, 18 or 24 months after initial diagnosis.
|
We expect to highlight linear correlation between NGAL/Urinary Creatinine and PIIINP/Urinary Creatinine ratios among patients with ARF.
|
3, 6, 12, 18 or 24 months after initial diagnosis.
|
|
Validation of high diagnostic performance of NGAL/Urinary Creatinine ratio to predict CRF occurrence.
Zeitfenster: 3, 6, 12, 18 or 24 months after initial diagnosis.
|
Sensitivity of NGAL/Urinary Creatinine ratio will be assessed at each time frame.
|
3, 6, 12, 18 or 24 months after initial diagnosis.
|
|
Validation of high diagnostic performance of PIIINP/Urinary Creatinine to predict CRF occurrence.
Zeitfenster: 3, 6, 12, 18 or 24 months after initial diagnosis.
|
Sensitivity of PIIINP/Urinary Creatinine ratio will be assessed at each time frame.
|
3, 6, 12, 18 or 24 months after initial diagnosis.
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- PROG/11/59
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Akute Niereninsuffizienz
-
Saint-Joseph UniversityBeendet
-
Hangzhou Endonom Medtech Co., Ltd.UnbekanntGuos viszerale Arterienrekonstruktion: Die erste Studie am Menschen zum WeFlow-JAAA-StentgraftsystemJuxta Renal Abdominal Aortenaneurysma ohne RupturChina
-
Akhilesh JainRekrutierungAortenaneurysma | Komplexe Aortenaneurysmen | Juxta Renal Abdominal Aortenaneurysma ohne RupturVereinigte Staaten
-
Mayo ClinicRekrutierungChronischer Kopfschmerz | Nussknacker-Syndrom, Nieren | Nussknacker-Phänomen, RenalVereinigte Staaten
-
Mayo ClinicAktiv, nicht rekrutierendKlarzelliges Nierenzellkarzinom | Urothelkarzinom | Chromophobes Nierenzellkarzinom | Papilläres Nierenzellkarzinom | Nieren-Onkozytom | Klarzelliger papillärer NierentumorVereinigte Staaten
-
Memorial Sloan Kettering Cancer CenterAktiv, nicht rekrutierendChromophobes Nierenzellkarzinom | Papilläres Nierenzellkarzinom | Nicht klassifiziertes Nierenzellkarzinom | Fortgeschrittenes oder metastasiertes nicht-klarzelliges Nierenzellkarzinom | Fumarathydratase-defizientes Nierenzellkarzinom | Succinat-Dehydrogenase-defizientes Nierenzellkarzinom | Collecting Duct Renal Cell CarcinomaVereinigte Staaten
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisAktiv, nicht rekrutierendNierenzellkarzinom | Chromophobes Nierenzellkarzinom | Papilläres Nierenzellkarzinom | Nicht klassifiziertes Nierenzellkarzinom | Collecting Duct Renal Cell Carcinoma | Translokation Nierenzellkarzinom | Nicht resezierbares fortgeschrittenes Nierenzellkarzinom | Metastasierendes Ncc-NierenzellkarzinomVereinigte Staaten
-
Leiden University Medical CenterRadboud University Medical Center; Health Holland; Dutch Kidney FoundationAbgeschlossenStörungen des Glukosestoffwechsels | Nierenerkrankungen | Diabetes Mellitus | Diabetische Nephropathien | Albuminurie | Mikroalbuminurie | Typ 2 Diabetes mellitus | Diabetische Nephropathie Typ 2 | Diabetische Komplikationen Renal | Süd asiatischNiederlande
-
Steno Diabetes Center CopenhagenKing's College London; Juvenile Diabetes Research Foundation; Guy's and St Thomas... und andere MitarbeiterNoch keine RekrutierungHypoxie | Diabetes mellitus, Typ 1 | Diabetische Nephropathien | Albuminurie | Nephropathie | Diabetische Komplikationen Renal | Diabetische Komplikationen Herz-KreislaufDänemark, Vereinigtes Königreich